Comparison of Fluorescence In Situ Hybridization And Immunohistochemistry Methods In Detecting HER2 Receptor Status In Breast Cancer
Breast Care · 14.11.2026
DOI: 10.1159/brc/abrag016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Care, online erschienen am 14.11.2026. Verfasst von Zeliha Esin Celik und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Purpose
Accurate determination of HER2 status is crucial for selecting appropriate targeted therapies in breast cancer (BC). This study aimed to evaluate the concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) methods in detecting HER2 receptor status across core needle biopsy (CNB), surgical resection (SR), and metastatic specimens, and to investigate the underlying reasons for any discordance.
Methods
A retrospective review of 563 BC specimens (241 CNB, 254 SR, and 68 metastatic) each one obtained from different 563 patients between January 2017 and June 2023 was conducted. All specimens had both HER2 IHC and dual-probe FISH results, which were evaluated according to the ASCO/CAP guidelines. The agreement between the two methods was statistically analyzed alongside various clinicopathologic parameters.
Results
The distribution of IHC scores across the cohort was 3.2% (0), 6.6% (1+), 80.8% (2+), and 9.4% (3%). Among the 455 IHC 2+ (equivocal) cases, 11.6% were FISH-positive, consistent with the literature. However, a significant discordance was observed in the 53 IHC 3+ (strongly positive) cases, with 54.7% (n=29) being FISH-nonamplified. This IHC 3+/FISH-negative discordance was highest in CNB specimens (68.8%), followed by SR (50.0%) and metastatic specimens (44.4%). In the non-equivocal sub-cohort (IHC 0, 1+, and 3+; n = 108), the overall concordance rate between IHC and FISH was 71.3% (Cohen's \(\kappa \) = 0.420, p < 0.001), indicating moderate agreement. With FISH as the reference standard, IHC demonstrated a high sensitivity of 92.3% and a negative predictive value (NPV) of 96.4%, whereas its specificity and positive predictive value (PPV) were lower at 64.6% and 45.3%, respectively. Furthermore, FISH positivity was significantly associated with estrogen and progesterone receptor negativity, as well as a higher histological grade (p < 0.05).
Conclusion
Our study reveals a remarkably high IHC 3+/FISH-negative discordance (54.7%) in a real-world setting, demonstrating that strong HER2 protein expression does not invariably guarantee gene amplification. This discrepancy is driven by a complex interplay of pre-analytical artifacts, manual scoring subjectivity at the 2+/3+ boundary, and biological factors such as chromosome 17 polysomy/pericentromeric gain or amplification-independent overexpression. Furthermore, limited sampling in core needle biopsies significantly amplifies this discordance due to spatial intratumoral heterogeneity. While proactive methodological adjustments such as increasing cell enumeration up to 60-100 cells can mitigate sampling risks, these findings confirm that relying on a single testing modality is insufficient. Ultimately, rigorous quality control, standardized pathological training, and mandatory reflex molecular testing are imperative to optimize patient selection for HER2-targeted therapies.
Zitieren
APA
Celik, Z. E., Demir, F., Yilmaz, S. S., Yonar, H., Çelik, M., & Ugras, S. (2026). Comparison of Fluorescence In Situ Hybridization And Immunohistochemistry Methods In Detecting HER2 Receptor Status In Breast Cancer. Breast Care. https://doi.org/10.1159/brc/abrag016
Vancouver
Celik ZE, Demir F, Yilmaz SS, Yonar H, Çelik M, Ugras S. Comparison of Fluorescence In Situ Hybridization And Immunohistochemistry Methods In Detecting HER2 Receptor Status In Breast Cancer. Breast Care. 2026. doi:10.1159/brc/abrag016
BibTeX
@article{Celik2026,
author = {Celik, Zeliha Esin and Demir, Fatih and Yilmaz, Sezer Seda and Yonar, Harun and Çelik, Murat and Ugras, Serdar},
title = {Comparison of Fluorescence In Situ Hybridization And Immunohistochemistry Methods In Detecting HER2 Receptor Status In Breast Cancer},
journal = {Breast Care},
year = {2026},
doi = {10.1159/brc/abrag016}
}
EUVIMED